CRVO CERVOMED INC

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025.

Panel Details

Title: “Small Firms Tackling Blockbuster Indications”

Date: Thursday, October 9, 2025

Time: 8:00 AM ET

To request a meeting or for more details about the Conference, please reach out to your institutional representative at Roth.

About CervoMed

CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company’s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB.

Investor Contact:

PJ Kelleher

LifeSci Advisors



617-430-7579



EN
02/10/2025

Underlying

CRVOCERVOMED INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERVOMED INC

 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunitie...

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025. Panel DetailsTitle: “Small Firms Tackling Blockbuster Indications”Date: Thursday, Octobe...

October 2, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Highlights Neflamapimod's Potential Benefits in Session on De...

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies (DLB) were highlighted in a presentation on advances in DLB drug development by Dr. James Galvin at the...

September 17, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Participate in Upcoming Investor Conferences BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September: H.C. Wainwright 27th Annual Global Investment ConferenceFormat: Presentation & 1x1 Investor MeetingsPresentation Date: Monday, September 8, 2025Presentation Time: 2:00 – 2:30 PM ETWebcast: Morgan Stanley’s 23rd Annual Global Healthcare Conf...

September 3, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Reports Second Quarter 2025 Financial Results and Provides Co...

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer’s disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary ac...

August 11, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Co...

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45th Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025. Presentation DetailsFormat: Fireside ChatDate: Tuesday, August 12, 2025Time: 2:00 PM ETWebcast Link: The webcast of th...

August 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch